# Can a Short Course of Rapamycin Before IVF Improve Pregnancy Outcomes for Women with Endometriosis? New research published in *Reproductive BioMedicine Online* suggests that taking the drug rapamycin for three months before an IVF cycle may significantly improve pregnancy and live birth rates for women with endometriosis-related infertility. The study followed 168 women through two IVF cycles and found that those who received rapamycin showed lower markers of cellular damage and aging in their follicular fluid (the fluid surrounding their eggs), produced more mature eggs, and had higher fertilization, implantation, clinical pregnancy, and live birth rates compared to women who received no adjuvant treatment. While these results are promising, the researchers emphasize that their findings need to be confirmed in prospective randomized controlled trials before rapamycin becomes a standard pre-IVF therapy. # Can a Short Course of Rapamycin Before IVF Improve Pregnancy Outcomes for Women with Endometriosis? ## Table of Contents - Key Points - Understanding Endometriosis and Infertility - Why IVF Outcomes Are Often Poorer for Women with Endometriosis - What Is Rapamycin? An Anti-Aging Drug Meets Fertility Treatment - Study Methods: How the Research Was Conducted - Key Findings: Detailed Results with All Data - Understanding the Results in Plain Terms - Clinical Implications: What This Means for Patients - Safety Considerations for Rapamycin Use - Limitations: What This Study Couldn't Prove - What Patients Should Know and Discuss with Their Doctor - Frequently Asked Questions - Source Information ## Key Points - In a study of 168 women with endometriosis, 3 months of rapamycin before IVF improved pregnancy and live birth rates. - Rapamycin treatment lowered oxidative stress and cellular senescence markers in follicular fluid, a sign of improved egg environment. - This was a retrospective cohort study, not a randomized trial, so causation is not proven. - Rapamycin is experimental for fertility; it is not standard care and requires medical supervision. - No fetal structural abnormalities were reported in the rapamycin group, but safety data remain limited. ## Understanding Endometriosis and Infertility Endometriosis is a chronic gynecological condition that affects an estimated 1 in 10 women of reproductive age. In this condition, tissue similar to the lining of the uterus (the endometrium) grows outside the womb — commonly on the ovaries, fallopian tubes, and the tissue lining the pelvis. This misplaced tissue responds to hormonal changes just like the uterine lining does, which can cause inflammation, scarring, severe pelvic pain, and, in many cases, fertility problems. The link between endometriosis and infertility has been well established in the medical literature. A 2013 systematic review and meta-analysis by Harb and colleagues, which the current study's authors reference, examined the effect of endometriosis on in vitro fertilization (IVF) outcomes and confirmed that women with endometriosis tend to have poorer results compared to women without the condition. A more recent 2022 meta-analysis by Qu and colleagues similarly examined the effect of endometriosis on IVF/intracytoplasmic sperm injection (ICSI) and perinatal outcomes. But why exactly does endometriosis harm fertility at the cellular level? The answer appears to involve two interconnected processes that are central to this study: **oxidative stress** (a state in which harmful free radicals overwhelm the body's antioxidant defenses, causing damage to cells and DNA) and **cellular senescence** (a state in which cells stop dividing and essentially "age" prematurely, releasing inflammatory signals that damage surrounding tissue). ## Why IVF Outcomes Are Often Poorer for Women with Endometriosis Researchers have been investigating the biological mechanisms behind endometriosis-related infertility for decades. The current study draws on a body of research that points to oxidative stress as a key culprit. For example, earlier studies by Da B.M. and colleagues (published in 2016 and 2018) found increased concentrations of 8-hydroxy-2′-deoxyguanosine (a marker of oxidative DNA damage) in the follicular fluid of infertile women with endometriosis, and suggested that oocyte (egg) oxidative DNA damage may be involved in minimal/mild endometriosis-related infertility. A 2020 study by Lin and colleagues, which this article's authors cite, went further: it found that **excessive oxidative stress in cumulus granulosa cells** (the supportive cells that surround and nourish the developing egg) induced cell senescence, and concluded this contributed to endometriosis-associated infertility. Other referenced studies have examined how endometriosis affects the oocyte itself. Mansour and colleagues (2010) demonstrated that endometriosis-induced alterations in mouse metaphase II oocyte microtubules and chromosomal alignment could be a possible cause of infertility. Sanchez and colleagues (2017) published a review asking directly whether oocyte quality is affected by endometriosis. Additional work by Ding and colleagues (2010) found that endometriotic peritoneal fluid — the fluid in the abdominal cavity of women with endometriosis — attenuated oocyte fertilization and embryo development. In short, the research landscape suggests that women with endometriosis face multiple barriers at the cellular level: their eggs may be of lower quality, the environment surrounding the eggs is more hostile due to oxidative stress, and the normal process of cellular renewal and repair is disrupted by premature senescence. ## What Is Rapamycin? An Anti-Aging Drug Meets Fertility Treatment Rapamycin — also known by its brand name sirolimus — is a medication that has been used for decades as an immunosuppressant in organ transplant patients (to prevent the body from rejecting a transplanted organ). In recent years, however, it has attracted enormous scientific interest for an entirely different reason: research has shown it can extend lifespan in animal models. The landmark 2009 study by Harrison and colleagues, published in the journal *Nature*, demonstrated that rapamycin fed late in life extends lifespan in genetically heterogeneous mice. A follow-up study by Miller and colleagues (2011) confirmed that rapamycin — but not resveratrol or simvastatin — extended the lifespan of these mice. Why would an immunosuppressant have anti-aging effects? The answer lies in a cellular pathway called the **mammalian target of rapamycin (mTOR) pathway**. This pathway acts as a master regulator of cell growth, metabolism, and survival. When mTOR signaling is overactive, it can promote cellular senescence — the process by which cells age prematurely. Rapamycin works by inhibiting mTOR, and in doing so, it appears to reduce markers of senescence. Apply this to endometriosis, and the logic becomes clear: if endometriosis-related infertility is driven in part by oxidative stress and premature cellular senescence in the ovarian environment, then a drug that reduces senescence — like rapamycin — could potentially improve the quality of the eggs and the follicular fluid environment. The current study's authors also point to evidence from other contexts supporting the potential of rapamycin in reproductive medicine. For example, Ahmadi and colleagues (2019) conducted a double-blind, phase II randomized clinical trial using sirolimus to treat patients with repeated implantation failure and elevated Th17/Treg ratio. Other studies, such as a 2019 exploratory trial by Chung and colleagues, found that topical rapamycin reduced markers of senescence and aging in human skin. And a 2018 randomized control trial by Kraig and colleagues established the feasibility and safety of rapamycin treatment in an older human cohort. ## Study Methods: How the Research Was Conducted This was a **retrospective cohort study**, meaning the researchers looked back at data from patients who had already undergone treatment, rather than assigning them randomly to treatment or placebo groups in real time. The study involved 168 infertile women with endometriosis who underwent two successive IVF cycles at a reproductive center. The patients were divided into two groups: - **Treatment group (n = 80):** Women who received 3 months of rapamycin treatment before their second IVF cycle - **Non-treatment group (n = 88):** Women who had no adjuvant treatment before their second IVF cycle The researchers compared the first and second IVF cycles both within each group (how did each group's second cycle compare to its first?) and between groups (how did the treatment group's second cycle compare to the non-treatment group's second cycle?). In addition to the clinical outcomes, the researchers collected **follicular fluid** — the nutrient-rich fluid that surrounds the egg inside the ovarian follicle — from a subset of patients in both IVF cycles. Follicular fluid samples were tested from 28 women in the treatment group and 32 women in the non-treatment group. These samples were analyzed for: - **Senescence-associated markers:** p16 and p21 (proteins that accumulate when cells stop dividing and become senescent) - **Oxidative stress markers:** 8-hydroxydesoxyguanosine (8-OHdG, a marker of DNA damage caused by free radicals) and malondialdehyde (MDA, a marker of damage to cell membranes and fats) - **Antioxidant markers:** superoxide dismutase (SOD) and glutathione peroxidase (GPx), two natural enzymes that protect cells from oxidative damage The study was conducted at the Reproductive Center of the First Hospital of Sun Yat-sen University in China. The senior author, Yi-Ping Zhong, is the Chief Physician of the center and has been practicing reproductive medicine for more than 30 years. The authors reported no financial or commercial conflicts of interest. The paper was received on April 28, 2023, accepted on July 25, 2023, and published online on July 29, 2023. ## Key Findings: Detailed Results with All Data The study produced a substantial body of results, examining both the molecular markers in the follicular fluid and the clinical outcomes of the IVF cycles. Here are the complete findings as reported by the researchers. ### Follicular Fluid Markers: Oxidative Stress Was Reduced When the researchers compared the follicular fluid from the second IVF cycles of both groups, they found dramatic differences in the markers of oxidative stress: - **Oxidative stress markers decreased:** Levels of 8-hydroxydesoxyguanosine (8-OHdG) and malondialdehyde (MDA) were significantly lower in the follicular fluid of the rapamycin treatment group compared to the non-treatment group. This difference was statistically highly significant, with a P-value of less than 0.001 for both markers (meaning there is less than a 0.1% chance that this result was due to random chance). - **Antioxidant markers increased:** Levels of superoxide dismutase (SOD) and glutathione peroxidase (GPx) — the body's natural defense enzymes against oxidative damage — were significantly higher in the treatment group than in the non-treatment group. Again, both differences were highly significant (P < 0.001). This indicates that rapamycin treatment was associated with a shift in the follicular fluid environment: less oxidative damage and stronger antioxidant protection. ### Follicular Fluid Markers: Cellular Senescence Was Reduced The expression of the senescence-related markers **p16** and **p21** was also significantly lower in the follicular fluid of the treatment group compared to the non-treatment group, with both differences again reaching a statistical significance of P < 0.001. This is an important molecular finding because p16 and p21 are well-established biomarkers of cellular senescence. When these proteins are present at high levels, it signals that cells have entered a state of arrested growth and are releasing inflammatory factors that can harm surrounding tissues — including developing eggs. Lower levels of p16 and p21 in the rapamycin-treated group suggest that the drug was doing exactly what it was designed to do: counteracting premature cellular aging in the ovarian environment. ### IVF Cycle Outcomes: More Eggs, Better Quality The second IVF cycle outcomes favored the treatment group across multiple measures: - **Fewer days of ovarian stimulation needed:** The treatment group required significantly fewer days of ovarian stimulation compared to the non-treatment group (P < 0.001). - **More oocytes obtained:** The treatment group had increased numbers of oocytes (eggs) retrieved compared to the non-treatment group (P < 0.001). - **More mature oocytes:** The number of mature oocytes (eggs that are fully developed and ready for fertilization) was also significantly higher in the treatment group (P < 0.001). Mature oocytes — known as metaphase II oocytes — are the ones that can be successfully fertilized to create embryos. Having more mature eggs is a critical advantage in IVF, as it gives the embryology lab more opportunities to create viable embryos for transfer. ### IVF Cycle Outcomes: Higher Fertilization, Implantation, and Pregnancy Rates The downstream clinical outcomes all improved in the treatment group: - **Fertilization rate:** Significantly higher in the treatment group (P = 0.008, meaning there is only a 0.8% chance this result was due to random chance) - **Implantation rate:** Significantly higher in the treatment group (P = 0.034, a 3.4% probability of being due to chance) - **Clinical pregnancy rate:** Significantly higher in the treatment group (P = 0.038, a 3.8% probability of being due to chance) - **Live birth rate:** Significantly higher in the treatment group (P = 0.003, a 0.3% probability of being due to chance) The live birth rate is widely considered the most meaningful outcome measure in fertility research because it represents the ultimate goal: a healthy baby born to the family. The fact that this measure showed the strongest statistical significance (P = 0.003) is encouraging. ### Fetal Safety Outcomes Importantly, **no structural abnormalities were seen in fetuses born to women treated with rapamycin**. This is a critical piece of safety data, as any medication used before or during pregnancy requires careful scrutiny regarding potential effects on the developing fetus. ## Understanding the Results in Plain Terms Let's unpack what these findings mean step by step. First, consider the environment in which an egg develops. Inside the ovary, each egg matures within a follicle — a fluid-filled sac that nourishes the egg. The quality of this follicular fluid matters enormously. If the fluid contains high levels of reactive oxygen species (unstable molecules that can damage cells), the egg inside that follicle will suffer the consequences: DNA damage, impaired maturation, and reduced ability to be fertilized and develop into a healthy embryo. In women with endometriosis, the follicular fluid tends to be more hostile — higher in oxidative stress markers and lower in antioxidants. This is where rapamycin appears to help. The study found that after 3 months of rapamycin treatment, the follicular fluid of these patients showed significantly lower oxidative damage markers (8-OHdG and MDA) and significantly higher antioxidant enzymes (SOD and GPx). The cellular senescence markers p16 and p21 also dropped. Second, consider what changed clinically. The women who took rapamycin needed fewer days of stimulation medication — which means their ovaries were responding more efficiently to the fertility drugs. They also produced more eggs and, crucially, more mature eggs. Mature eggs are the ones that can be fertilized, so this improvement directly translates into better fertilization rates. Then, in a cascade effect visible throughout the IVF process, the improved egg quality led to better embryos, which led to better implantation rates, higher clinical pregnancy rates, and ultimately higher live birth rates. The study's authors describe the treatment's apparent dual mechanism: it reduced oxidative stress in the follicular environment while also suppressing cellular senescence. These two processes are intertwined — oxidative stress can trigger senescence, and senescent cells produce more oxidative stress — so rapamycin may be breaking a vicious cycle that undermines fertility in women with endometriosis. ## Clinical Implications: What This Means for Patients The potential implications of this research are substantial for the estimated millions of women worldwide who struggle with endometriosis-related infertility. Currently, women with endometriosis who pursue IVF often have lower success rates than women without the condition, as documented in the meta-analyses by Harb and colleagues (2013) and Qu and colleagues (2022). The underlying reasons include poor oocyte quality, reduced ovarian reserve, and a hostile follicular environment. Until now, there has been no targeted treatment to address these molecular-level problems before an IVF cycle. This study suggests that a relatively simple intervention — a 3-month course of rapamycin before IVF — could shift the balance in favor of these patients. The reductions in oxidative stress markers and senescence markers in the follicular fluid provide a plausible biological explanation for the improved clinical outcomes, rather than just an empirical association. If confirmed by larger randomized controlled trials, this treatment could become a standard "pre-conditioning" step for endometriosis patients planning IVF. Because rapamycin is already an approved medication with a well-documented pharmacological profile, the path to clinical adaptation could potentially be faster than for a completely new drug. The researchers also note that rapamycin has been studied in other reproductive contexts. The Ahmadi 2019 trial, for instance, used sirolimus (the same drug, with a different name) in patients with repeated implantation failure and elevated Th17/Treg ratios — a different patient population but one that also faces immune-related barriers to implantation. This suggests the drug's benefits might extend beyond endometriosis patients specifically. ## Safety Considerations for Rapamycin Use Because rapamycin is an immunosuppressant, patients and physicians naturally want to understand its safety profile — particularly in women who are hoping to become pregnant. The current study provides some reassuring data: no structural abnormalities were observed in fetuses born to women who had taken rapamycin. However, this is a small cohort, and the follow-up time is limited, so long-term safety data remain incomplete. The study's authors reference several earlier reports on the use of rapamycin-family drugs around pregnancy: - **Guardia and colleagues (2006)** reported a case of pregnancy under sirolimus-based immunosuppression in a transplant patient. - **Jankowska and colleagues (2004)** reported the absence of teratogenicity (birth defect-causing effects) of sirolimus used during early pregnancy in a liver transplant recipient. - **Margoles and colleagues (2014)** described a successful maternal and fetal outcome in a kidney transplant patient with everolimus (a medication closely related to rapamycin) exposure throughout pregnancy. - **Sifontis and colleagues (2006)** reviewed pregnancy outcomes in solid organ transplant recipients exposed to mycophenolate mofetil or sirolimus. However, it is important to note that rapamycin is not currently approved for use in pregnancy. The standard medical guidance for organ transplant patients who become pregnant while on rapamycin typically involves switching to other immunosuppressants, unless the risks of switching outweigh the benefits. Any use of rapamycin in a fertility treatment context would require careful discussion between the patient and their reproductive specialist, and ideally within the framework of a clinical trial. Furthermore, the dosing, timing, and duration of rapamycin treatment in this study — 3 months before the IVF cycle — is specific to this research protocol. Patients should not attempt to obtain and take rapamycin on their own. This is very much a medication that requires expert medical supervision. ## Limitations: What This Study Couldn't Prove It is essential to view these promising findings with appropriate scientific caution. The study has several important limitations that the authors themselves acknowledge. First and foremost, this was a **retrospective cohort study**, not a prospective randomized controlled trial. In a retrospective design, researchers analyze data that was already collected, and patients were not randomly assigned to treatment or non-treatment groups. This means there may have been **selection bias**: the patients who received rapamycin may have differed from those who did not in ways that influenced their outcomes, such as age, socioeconomic status, or severity of endometriosis. Second, the study does not establish **causation**. While the researchers found a clear association between rapamycin treatment and improved outcomes, an association alone cannot prove that rapamycin caused the improvement. This is precisely why the authors state in their conclusion: "This result needs to be further investigated in prospective randomized controlled clinical trials." Third, the sample sizes for the follicular fluid analysis were relatively small — 28 women in the treatment group and 32 in the non-treatment group. While the statistical results were highly significant, a larger sample would provide more robust evidence. Fourth, the study did not report on some important clinical variables that could influence outcomes, such as the women's ages, body mass index, duration of infertility, or the stage of endometriosis. These factors can significantly affect IVF success rates, and if they were unevenly distributed between the two groups, they could confound the results. Fifth, the study only followed patients through the birth of their child. Longer-term follow-up is needed to assess the health and development of the children born after maternal rapamycin exposure, as well as the ongoing health of the mothers. Finally, the study does not provide data on the optimal dose of rapamycin, the optimal duration of treatment, or whether some subgroups of endometriosis patients might benefit more than others. ## What Patients Should Know and Discuss with Their Doctor For women with endometriosis who are considering IVF, this research offers a source of cautious hope — but not yet a reason to change treatment plans unilaterally. Here is what the study suggests patients should know and discuss with their fertility specialist: 1. **Understand your diagnosis.** If you have endometriosis-associated infertility, know that your IVF outcomes may be affected by the condition. Oxidative stress and cellular senescence in the ovarian environment are part of the problem. This is a biological reality, not a reflection of anything you did wrong. 1. **Ask about rapamycin in a clinical trial context.** Short-term rapamycin therapy before IVF is an emerging treatment, not yet a standard of care. Ask your reproductive endocrinologist whether any clinical trials are enrolling patients with endometriosis for rapamycin pre-treatment before IVF. 1. **Do not self-medicate.** Rapamycin is a prescription immunosuppressant with potential side effects and interactions. Taking it without medical supervision could be harmful, especially for women who may become pregnant. 1. **Focus on what is proven.** While waiting for more research, continue to follow evidence-based practices that are known to improve IVF outcomes for endometriosis patients, including working with an experienced reproductive center, managing pain and inflammation with your doctor, and optimizing your overall health before starting a cycle. 1. **Ask about follicular fluid testing.** If you have access to a research center, consider asking whether your follicular fluid will be analyzed for oxidative stress and senescence markers as part of a research protocol. This can help advance scientific knowledge and may eventually lead to personalized pre-IVF treatments. 1. **Stay informed.** The research field is moving quickly. Prospective randomized controlled trials of rapamycin for endometriosis-related infertility are the logical next step, and their results — when published — will be important to review with your doctor. The bottom line: This study provides the first clinical evidence in patients that short-term rapamycin treatment before IVF is associated with improved reproductive outcomes — including a significantly higher live birth rate — alongside reduced oxidative stress and senescence in the follicular fluid of women with endometriosis. But it is a single retrospective cohort study, and the authors themselves call for prospective randomized controlled clinical trials to confirm these findings. For now, the most appropriate response for patients is informed optimism and a careful conversation with their fertility specialist about whether they are a candidate for rapamycin treatment within a clinical research framework. ## Frequently Asked Questions ### How does endometriosis affect IVF success rates? Endometriosis can lower IVF success. The condition creates a hostile environment around the eggs, with higher oxidative stress and premature cellular aging. This can reduce egg quality, fertilization, implantation, and pregnancy rates compared to women without the condition. However, outcomes vary, and treatment depends on your specific situation. ### What did the rapamycin study test and what were the main results? In a retrospective study of 168 women with endometriosis, half received rapamycin for three months before their second IVF cycle. Compared to no treatment, the rapamycin group had more mature eggs, higher fertilization, implantation, clinical pregnancy, and live birth rates. Follicular fluid also showed lower oxidative stress and aging markers. ### Is rapamycin currently recommended for endometriosis patients before IVF? No, not as standard care. Rapamycin before IVF is experimental. The study's authors say their promising findings need confirmation in prospective randomized controlled trials. Patients should ask their fertility specialist about enrolling in clinical trials rather than seeking rapamycin on their own. ### What are the limitations of this rapamycin study? This was a retrospective cohort study, not a prospective randomized trial, so it cannot prove rapamycin caused the improvement. Selection bias is possible. Only a small subset had follicular fluid analyzed, and the study didn't report patients' ages, BMI, infertility duration, or endometriosis stage, which could affect results. ### What should I discuss with my doctor about rapamycin and IVF? Ask whether any clinical trials are enrolling endometriosis patients for rapamycin before IVF. Do not self-medicate. Focus on proven treatments for endometriosis, manage pain and inflammation, and optimize health before a cycle. Ask if follicular fluid testing is offered in a research setting to guide future care. ### Should I seek a second opinion about whether to take rapamycin before my IVF cycle if I have endometriosis? Taking rapamycin for three months before IVF is an emerging, not standard, treatment for endometriosis-related infertility. A retrospective study linked it to higher live birth rates and lower oxidative stress and cellular senescence markers in follicular fluid. However, these findings are preliminary and do not prove that rapamycin caused the improvement; randomized controlled trials are still needed. Because rapamycin is an immunosuppressant and not approved for use around pregnancy, it should only be considered under expert supervision or in a clinical trial. A second opinion can help you decide whether this experimental approach is appropriate for your specific case. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information This patient-friendly article is based on peer-reviewed research published in *Reproductive BioMedicine Online*. - **Original article title:** A cohort study on IVF outcomes in infertile endometriosis patients the effects of rapamycin treatment - Reproductive BioMedicine Online --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/can-a-short-course-of-rapamycin-before-ivf-improve-pregnancy-outcomes-for-women-with-endometriosis